Impax Laboratories (IPXL)
Create an AlertIPXL Key Stats
| Income Statement | |
| Revenue TTM | 601.61M |
| Revenue Quarterly YoY Growth | 15.49% |
| EPS Diluted TTM | 2.180 |
| EPS Diluted Quarterly YoY Growth | 761.1% |
| Net Income TTM | 148.95M |
| Profitability | |
| Gross Profit Margin Quarterly | 38.97% |
| Profit Margin Quarterly | 71.01% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 1.291B |
| Enterprise Value | 941.78M |
| PE Ratio TTM | 8.648 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.0674 |
| Price / Book Value | 1.617 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | 48.39M |
| Return on Equity | 21.61% |
IPXL News
- Does Restless Legs Syndrome Really Shorten Life Span? Fool Jun 17
- Impax Reduces Workforce - Analyst Blog Zacks Jun 6
- Impax Reduces Workforce Jun 6
- Filthy Pharma: Justice Department Taking "Especially Hard Look" At Manufacturing... Jun 6
- Impax Reduces Workforce - Analyst Blog Zacks Jun 6
- Bernstein Liebhard LLP Announces An Investigation Concerning Impax Laboratories,... Jun 6
- Impax Labs to Cut Jobs Fool Jun 5
- Endo Health to slash 15 pct jobs, looks to sell some assets Jun 5
- Impax Labs cuts 110 manufacturing and sales jobs Jun 5
- Impax cuts 110 jobs, expects to save $15 million Jun 5
IPXL Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Impax Laboratories is down 12.61% over the last year vs S&P 500 Total Return up 24.84%, Salix Pharmaceuticals up 26.86%, and Warner Chilcott up 48.16%.
IPXL Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these IPXL related companies
Pro Ratings for IPXL
Pro Report PDF for IPXL
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download IPXL Pro Report PDF
Pro Strategies Featuring IPXL
Did Impax Laboratories make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
IPXL Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
IMPAX Laboratories, Inc. is a technology-based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities. It was founded by Larry Hsu in 1995.
Other IPXL Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IPXL | 18.85 | +0.00 | +0.00% | 1.291B |
